Market Place
Sourcing Support
CHMP Recommends Approval of Lecanemab in the EU
14 Nov 2024 //
PR NEWSWIRE
Eisai Upgrades Leqembi Sales Forecast To JPY 42.5 bn For Fis 2024
07 Nov 2024 //
PR NEWSWIRE
BioArctic Invites Q3 2024 Report Presentation on November 14
06 Nov 2024 //
PR NEWSWIRE
BrainTransporter™ Enhances Antibody Delivery to the Brain
06 Nov 2024 //
PR NEWSWIRE
Lecanemab Data at CTAD: Early Initiation & Long-Term Benefits
31 Oct 2024 //
PR NEWSWIRE
Professor Lars Lannfelt Receives CTAD Lifetime Achievement Award
30 Oct 2024 //
PR NEWSWIRE
Leqembi® revenue totaled JPY 10 billion in the third quarter 2024
30 Oct 2024 //
PR NEWSWIRE
Lifetime Achievement Award, lecanemab and biomarkers at CTAD Conf
24 Oct 2024 //
PR NEWSWIRE
Eisai To Request Reconsideration Of Lecanemab In Australia
16 Oct 2024 //
PR NEWSWIRE
Exidavnemab Phase 1 Study Results Published In Clinical Pharmacology
27 Aug 2024 //
PR NEWSWIRE
BioArctic Comments On Lecanemab Approval Rumors In Britain
22 Aug 2024 //
PR NEWSWIRE
BioArctic To Present Q2 2024 Report On August 29
19 Aug 2024 //
PR NEWSWIRE
Leqembi Revenue Doubles In Q2 2024
01 Aug 2024 //
PR NEWSWIRE
Long-Term Lecanemab Data Shows Increased Benefit With Maintained Safety
30 Jul 2024 //
PR NEWSWIRE
CHMP has adopted a negative opinion on lecanemab for the EU
26 Jul 2024 //
PR NEWSWIRE
Leqembi approved for the treatment of Alzheimer`s disease in Hong Kong
10 Jul 2024 //
PRESS RELEASE
Eisai and Biogen launch Alzheimer`s drug Leqembi in China
28 Jun 2024 //
REUTERS
Eisai Projects Leqembi Revenue JPY 56.5B For FY2024
15 May 2024 //
PR NEWSWIRE
Eisai Initiates Leqembi Rolling BLA For Subcutaneous Maintenance Dosing
14 May 2024 //
PR NEWSWIRE
Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024
24 Apr 2024 //
PR NEWSWIRE
BioArctic, Eisai Sign BAN2802 Research Evaluation Agreement
20 Apr 2024 //
PR NEWSWIRE
The Nomination Committee Proposes Board, Chair Election for BioArctic AB
16 Apr 2024 //
PR NEWSWIRE
BioArctic`s ESG Focus Qualifies for Nasdaq Stockholm Index
10 Apr 2024 //
PR NEWSWIRE
Submission of Leqembi® sBLA for the treatment of early AD to the FDA completed
31 Mar 2024 //
PR NEWSWIRE
EU regulator delays decision on Eisai-Biogen Alzheimer`s drug
23 Mar 2024 //
REUTERS
BioArctic: Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer`s
19 Mar 2024 //
PR NEWSWIRE
BioArctic: New data on lecanemab presented at the 2024 AD/PD™ congress
11 Mar 2024 //
PR NEWSWIRE
BioArctic`s partner Eisai presents sales simulation for Leqembi
07 Mar 2024 //
PR NEWSWIRE
Sales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023
05 Feb 2024 //
PR NEWSWIRE
The EMA`s SAG to discuss the MAA for lecanemab: BioArctic
11 Jan 2024 //
PR NEWSWIRE
EQT introduces the EQT Healthcare Growth Strategy
09 Jan 2024 //
PR NEWSWIRE
Leqembi® approved for the treatment of Alzheimer`s disease in China
09 Jan 2024 //
PR NEWSWIRE
Update relating to LEQEMBI from presentation of quarterly report published
07 Nov 2023 //
PR NEWSWIRE
LEQEMBI® Q3 2023 sales published - 0.4 billion yen recorded in the period
07 Nov 2023 //
PR NEWSWIRE
BioArctic receives patent in Japan for antibodies targeting Parkinson`s disease
23 Aug 2023 //
PR NEWSWIRE
Latest data on lecanemab to be presented at AAIC 2023
11 Jul 2023 //
PR NEWSWIRE
Marketing Authorisation Application for lecanemab submitted in Great Britain
21 May 2023 //
PR NEWSWIRE
Societal value of lecanemab in Japan published in Neurology and Therapy
17 May 2023 //
PR NEWSWIRE
BioArctic: New lecanemab-data presented at AD/PD 2023
03 Apr 2023 //
PR NEWSWIRE
BioArctic hires Anders Martin-Löf as new CFO
28 Feb 2023 //
PR NEWSWIRE
BioArctic: Lecanemab receives priority review status in Japan
29 Jan 2023 //
PR NEWSWIRE
EMA accepts MAA for lecanemab as treatment for Alzheimer`s disease: BioArctic
26 Jan 2023 //
PR NEWSWIRE
BioArctic`s partner Eisai submits MAA for lecanemab for Alzheimer`s disease
10 Jan 2023 //
PR NEWSWIRE
FDA approves LEQEMBI under the Accelerated Approval pathway
09 Jan 2023 //
PR NEWSWIRE
Eisai submits supplemental BLA to FDA for traditional approval of LEQEMBI
08 Jan 2023 //
PR NEWSWIRE
BioArctic moves to Nasdaq Stockholm Large Cap
02 Jan 2023 //
PR NEWSWIRE
BioArctic`s partner Eisai initiates BLA submission of data for lecanemab
21 Dec 2022 //
PRNEWSWIRE
BioArctic expands portfolio with alpha-synuclein Brain Transporter project
17 Nov 2022 //
PRNEWSWIRE
BioArctic receives patent in US for blood-brain barrier transport technology
14 Nov 2022 //
PRNEWSWIRE
BioArctic develops new treatment for Gaucher’s disease
09 Nov 2022 //
PHARMABIZ
Lecanemab PIII study in Alzheimer`s disease meets primary & secondary endpoints
27 Sep 2022 //
PRNEWSWIRE
BioArctic receives new drug substance patent in the US for ABBV-0805
05 May 2022 //
PRNEWSWIRE
AbbVie breaks off Parkinson`s deal with biotech partner
21 Apr 2022 //
ENDPTS
Invitation to presentation of BioArctic`s Q1 Report
20 Apr 2022 //
PRNEWSWIRE
Latest lecanemab data to be presented at the AD/PD congress
11 Mar 2022 //
PRNEWSWIRE
BioArctic continues to build its commercial organization
18 Feb 2022 //
PRNEWSWIRE
New data on lecanemab presented at the CTAD Alzheimer conference
15 Nov 2021 //
PRNEWSWIRE
BioArctic develops new antibody treatment for ALS
15 Nov 2021 //
PRNEWSWIRE
New data published on ABBV-0805 in Neurobiology of Disease
08 Nov 2021 //
PRNEWSWIRE
FDA grants Breakthrough Therapy designation for lecanemab in Alzheimer`s disease
23 Jun 2021 //
PRNEWSWIRE
